The Comeback Begins? Positive Signs Seen For Humira Biosimilars In US

Sandoz Gets Adalimumab Bump And Teva/Alvotech Strike Deal, As Market Share Doubles In Q1

 
• By David Wallace
  
Setback/comeback written on wooden blocks
Humira biosimilars are bouncing back after initial slow uptake • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products